Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review

被引:0
作者
Schmitt, Lisa [1 ]
Theiler-Schwetz, Verena [1 ]
Sadoghi, Patrick [2 ]
Trummer, Christian [1 ]
Pilz, Stefan [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Auenbruggerplatz 15, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Orthopaed & Trauma, Graz, Austria
来源
ARCHIVES OF ENDOCRINOLOGY METABOLISM | 2024年 / 68卷
关键词
Hypercalcemia; denosumab; primary hyperparathyroidism; parathyroid carcinoma; rebound; GIANT-CELL TUMOR; DISCONTINUATION; MANAGEMENT; THERAPY;
D O I
10.20945/2359-4292-2024-0035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented with rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma. This nonPTH-dependent hypercalcemia resolved after re-initiation of denosumab. We performed a systematic literature review on rebound hypercalcemia after denosumab cessation and identified 52 individual patient cases. Children appear to be more prone to developing rebound hypercalcemia, which could be attributed to their higher baseline bone turnover, underlying conditions, or denosumab dosage regimens. In most cases, patients initially presented with acute and often severe symptoms of hypercalcemia that occur from 1.75 to 9 months after denosumab cessation (4 to 9 months in adults). Most effective treatment approaches to sufficiently decrease serum calcium levels were bisphosphonates or re-administration of denosumab. A watch and wait strategy may be sufficient in asymptomatic cases, which are less common and probably underdiagnosed. Subsequent antiresorptive treatment after denosumab cessation, which is a common practice in osteoporosis treatment, may reduce the risk of rebound hypercalcemia. As denosumab is a frequently used drug in patients with advanced malignant diseases and rebound hypercalcemia with low PTH levels may raise the suspicion for skeletal metastases, awareness of this rebound effect may be for particular relevance in such settings.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Treatment of Vasovagal Syncope Associated with Asystole: Literature Review and Case Report of Long-term Follow-up
    Pevzner, A., V
    Kuchinskaya, E. A.
    Kiktev, V. G.
    Kheimets, G., I
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (02) : 315 - 322
  • [22] Persistent Hypercalcemia Crisis and Recurrent Acute Pancreatitis Due to Multiple Ectopic Parathyroid Carcinomas: Case Report and Literature Review of Mediastinal Parathyroid Carcinoma
    Jiajue, Ruizhi
    Song, An
    Wang, Ou
    Li, Wei
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [23] Management of Cholinergic Rebound After Abrupt Withdrawal of Clozapine: A Case Report and Systematic Literature Review
    Bickerton, Lucy
    Kuriakose, Jisha Lovin
    [J]. JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2024, 65 (01): : 76 - 88
  • [24] Clinical symptoms and sonographic follow-up after surgical treatment of nonparasitic liver cysts
    Scheuerlein, Hubert
    Rauchfuss, Falk
    Franke, Julia
    Jandt, Karin
    Dittmar, Yves
    Trebing, Gudrun
    Settmacher, Utz
    [J]. BMC SURGERY, 2013, 13
  • [25] Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated?
    in't Veld, Eva A. Huis
    van Coevorden, Frits
    Grunhagen, Dirk J.
    Smith, Myles J.
    van Akkooi, Alexander C. J.
    Wouters, Michel W. J. M.
    Hayes, Andrew J.
    Verhoef, Cornelis
    Strauss, Dirk C.
    van Houdt, Winan J.
    [J]. CANCER, 2019, 125 (05) : 735 - 741
  • [26] Is lifelong follow-up necessary for low-risk papillary thyroid carcinoma? Case series and a review of the literature
    Bahcecioglu, Adile Begum
    Erdogan, Murat Faik
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 : S1009 - S1013
  • [27] Long-term surveillance of intrahepatic cholangiocarcinoma diagnosed after 20 years follow-up for hepatic hemangioma: a case report and literature review
    Wu, Yuzhe
    Wang, Weimin
    Shu, Bin
    Li, Min
    Xu, Jianjun
    Zheng, Qichang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (05): : 1206 - 1211
  • [28] Imaging technologies in the differential diagnosis and follow-up of brown tumor in primary hyperparathyroidism: Case report and review of the literature
    Diacinti, Davide
    Cipriani, Cristiana
    Biamonte, Federica
    Pepe, Jessica
    Colangelo, Luciano
    Kripa, Endi
    Iannacone, Antonio
    Orlandi, Martina
    Guarnieri, Vito
    Diacinti, Daniele
    Minisola, Salvatore
    [J]. BONE REPORTS, 2021, 14
  • [29] Tunnel Fenestration of the Mandibula after Unsuccessful Post Traumatic Treatment: A Case Report of the One Year Follow-Up
    Gillner, Peter
    Mosch, Richard
    von See, Constantin
    [J]. DENTISTRY JOURNAL, 2023, 11 (02)
  • [30] Implant Treatment with 12-Year Follow-Up in a Patient with Severe Chronic Periodontitis: A Case Report and Literature Review
    Seki, Keisuke
    Hagiwara, Yoshiyuki
    [J]. CASE REPORTS IN DENTISTRY, 2019, 2019